Resolvin E1 candidate (TP-317) represents a novel approach to treating inflammatory bowel disease based on activating inflammation resolution and tissue repair pathways that directly promote mucosal healing
BRANFORD, CT – (July 13, 2019) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company with platform technology that is developing Resolvin-based therapies for inflammatory diseases, will be presenting data on its lead candidate, TP-317, for treatment of inflammatory bowel disease (IBD) at the Kenneth Rainin Foundation’s annual Innovations Symposium. TP-317 is a new molecular entity that delivers Resolvin E1 (RvE1), an endogenous lipid mediator that promotes inflammation resolution and tissue repair without suppressing the immune system. TP-317 is being developed as a potential first-in-class, safe, oral agent for induction and maintenance of remission of ulcerative colitis and Crohn’s disease.
“New oral IBD therapies are expected to generate $8.5 billion in sales globally by 2027. As a first-in-class Resolvin-based oral therapy, TP-317 offers a new approach for treating IBD that has prospects to become an important therapeutic option for patients who are not well controlled on 5-ASA but not ready to escalate to biologics and other immunosuppressive drugs that have risk of significant side effects and in many cases black box warnings.” stated Gary Mathias, Co-Founder and CEO of Thetis Pharmaceuticals. “Based on its mechanism of action and anticipated profile as a safe, oral drug, TP-317 could be well-suited for this patient segment. The data on TP-317 presented at the KRF Innovation Symposium provide compelling evidence supporting clinical investigation, which we plan to begin in 2020.”
The Kenneth Rainin Foundation’s eighth annual Innovations Symposium from July 13-15 is dedicated to promoting cutting-edge thinking about IBD. This event brings together researchers, trainees and clinicians to encourage dialogue and build bridges that enhance IBD research.
About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company with platform technology developing novel Resolvin-based therapies for the treatment of IBD and other inflammatory diseases. Thetis’ proprietary HEALER platform enables the pharmaceutical development of Resolvins, a unique class of molecules with the potential to transform the treatment of chronic inflammatory diseases. Thetis’ lead candidate, TP-317, is a new molecule that delivers RvE1, an endogenous lipid mediator that resolves inflammation and promotes mucosal tissue repair. TP-317 is being developed as a safe, oral therapy for treatment of ulcerative colitis and Crohn’s disease.
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) and follow Thetis on Twitter (@thetispharma).
Director of Business Development